We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$141M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+186.12%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$147M
AUM Growth
+$50.5M
(+52%)
Cap. Flow
-$12.7M
Cap. Flow
% of AUM
-8.64%
Top 10 Holdings %
Top 10 Hldgs %
79.38%
Holding
35
New
7
Increased
4
Reduced
6
Closed
5
Top Buys
| 1 |
Praxis Precision Medicines
PRAX
|
+$6.2M |
| 2 |
TERN
Terns Pharmaceuticals
TERN
|
+$3.1M |
| 3 |
Minerva Neurosciences
NERV
|
+$2.63M |
| 4 |
Tango Therapeutics
TNGX
|
+$2.44M |
| 5 |
Design Therapeutics
DSGN
|
+$1.18M |
Top Sells
| 1 |
TRML
Tourmaline Bio
TRML
|
+$12.8M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$8.47M |
| 3 |
Insmed
INSM
|
+$2.32M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$1.95M |
| 5 |
Krystal Biotech
KRYS
|
+$1.87M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERN
1
DELISTED
Terns Pharmaceuticals
TERN
| $25.7M | 17.48% |
637,095
+134,298
| +27% | +$3.1M |
|
|
2
Praxis Precision Medicines
PRAX
$9.14B
| $24.5M | 16.62% |
83,036
+33,285
| +67% | +$6.2M |
|
|
CDTX
3
DELISTED
Cidara Therapeutics
CDTX
| $19.7M | 13.37% |
89,145
-52,384
| -37% | -$8.47M |
|
4
Ocular Therapeutix
OCUL
$2.12B
| $12.8M | 8.68% |
1,052,995
-112,211
| -10% | -$1.36M |
|
|
WHWK
5
Whitehawk Therapeutics
WHWK
$188M
| $8.25M | 5.6% |
3,410,402
| – | – |
|
|
DRUG
6
Bright Minds Biosciences
DRUG
$726M
| $6.59M | 4.48% |
84,477
-398
| -0.5% | -$26.6K |
|
7
Compass Therapeutics
CMPX
$394M
| $5.87M | 3.99% |
1,093,300
+253,210
| +30% | +$1.17M |
|
8
Jazz Pharmaceuticals
JAZZ
$15B
| $4.93M | 3.35% |
29,008
+3,894
| +16% | +$597K |
|
|
9
Insmed
INSM
$23.9B
| $4.5M | 3.06% |
25,878
-12,714
| -33% | -$2.32M |
|
10
argenx
ARGX
$53.8B
| $4.08M | 2.77% |
4,851
-1,528
| -24% | -$1.31M |
|
11
Surrozen
SRZN
$254M
| $4.03M | 2.74% |
178,415
| – | – |
|
12
Amylyx Pharmaceuticals
AMLX
$2.02B
| $4.03M | 2.73% |
333,258
| – | – |
|
|
13
Minerva Neurosciences
NERV
$187M
| $2.85M | 1.94% |
+709,500
| New | +$2.63M |
|
|
14
Tango Therapeutics
TNGX
$4.83B
| $2.51M | 1.7% |
+282,732
| New | +$2.44M |
|
15
Taysha Gene Therapies
TSHA
$1.64B
| $2.5M | 1.7% |
454,827
| – | – |
|
16
Zymeworks
ZYME
$1.81B
| $2.11M | 1.43% |
80,143
| – | – |
|
17
Oculis Holding
OCS
$781M
| $2.03M | 1.38% |
101,777
| – | – |
|
|
18
Design Therapeutics
DSGN
$854M
| $1.42M | 0.96% |
+150,906
| New | +$1.18M |
|
19
Inhibrx
INBX
$1.37B
| $1.29M | 0.88% |
16,377
| – | – |
|
20
United Therapeutics
UTHR
$22.4B
| $1.12M | 0.76% |
2,296
| – | – |
|
21
Verastem
VSTM
$489M
| $1.11M | 0.75% |
143,446
| – | – |
|
|
MAZE
22
Maze Therapeutics
MAZE
$1.65B
| $829K | 0.56% |
+20,000
| New | +$687K |
|
23
MoonLake Immunotherapeutics
MLTX
$1.63B
| $781K | 0.53% |
+59,280
| New | +$699K |
|
24
Sutro Biopharma
STRO
$431M
| $780K | 0.53% |
+67,451
| New | +$640K |
|
25
Dianthus Therapeutics
DNTH
$5.54B
| $689K | 0.47% |
16,708
-8,292
| -33% | -$321K |
|
Similar funds
MQWP
OWM
VT
API
APW
SM
VEM
MWM